Introduction

Diabetes mellitus is one of the most common chronic diseases in nearly all countries; it is increasing rapidly in every part of the world, to the extent that it has now assumed epidemic proportions. In 2012, more than 382 million people had diabetes and this is expected to rise to 595 million by 2035 [1] rendering previous estimates very conservative and in the US, diabetes is the fifth leading cause of death for men [2]. It is also a leading cause of death in most developed countries [1].

Several behavioral and environmental factors have contributed to the rise in diabetes incidence in industrialized countries, including overweight (Body Mass Index [BMI], ≥25 kg/m²), obesity (BMI, ≥30 kg/m²), physical inactivity, and increased caloric consumption; these have all been shown to be major risk factors for the development of type 2 diabetes, regardless of age and sex [3].

Diabetes mellitus is associated with both macrovascular (including cardiovascular disease) and microvascular (including retinopathy, nephropathy, and neuropathy) complications [4,5]. People with diabetes are at a greater risk of developing Cardiovascular Diseases (CVD), such as heart attack and stroke.

Diabetes has been associated with sexual dysfunction in men [6,7]. Diabetes is an established risk factor for sexual dysfunction in men; a threefold increased risk of Erectile Dysfunction (ED) was documented in diabetic compared with nondiabetic men [6,8]. It is still not clear whether hyperglycemia, which is a main determinant of vascular diabetic complications, may participate in the pathogenic mechanisms of sexual dysfunction in diabetes. Otherwise, diabetic people may present with several clinical conditions, including hypertension, cigarette smoking, obesity, metabolic syndrome or dyslipidemia, which are themselves risk factors for sexual dysfunction in both sexes [9,10].

Erectile Dysfunction

Erectile Dysfunction (ED) is defined as the persistent inability to achieve or maintain penile erection for successful sexual intercourse [11] causing decreased quality of life in men [12,13]. Epidemiological data have shown a high prevalence and incidence of ED worldwide. ED is a common sexual disorder that increases with age. According to a recent analysis of published works on the prevalence of sexual dysfunction by the International Consultation Committee for Sexual Medicine on Definitions/Epidemiology/Risk Factors for Sexual Dysfunction [14] the prevalence of ED was 1%-10% in men younger than 40 years, 2%-9% among men between 40 and 49 years, and it increased to 20%-40% among men between 60-69 years, reaching the highest rate in men older than 70 years (50%-100%).

In the Massachusetts Male Aging Study [6] diabetic men showed a threefold probability of having ED than men without diabetes; moreover, the age-adjusted risk of ED was doubled in diabetic men compared with those without diabetes [15]. In addition, it has been estimated that the worldwide prevalence of ED will rise to 322 million cases by the year 2025 [16,17]. Several cross-sectional and longitudinal studies showed an association between ED and most of the cardiovascular risk factors, such as diabetes [6,12,18], smoking [19], hypertension [20], hyperlipidemia [21], depression [22], metabolic syndrome [23], lower urinary tract symptom [24], and poor health state [12]. Moreover, ED can be easily detected by having male patients complete standardized questionnaires investigating their...
sexual function. One of the most practical questionnaires that is administered is the International Index of Erectile Function (IIEF) [25].

**ED and Diabetes: Risk Factors and Association**

Diabetes mellitus is one of the predominant risk factors of erectile dysfunction and also one of the most difficult to treat. Approximately 50% of diabetic men will suffer from ED within 10 years of the diagnosis. Epidemiological studies suggest that both type 1 and type 2 diabetes are associated with an increased risk of ED, which is reported to occur in ≥50% of men with diabetes worldwide [20,26]. The occurrence of ED is 10–15 years earlier in men with diabetes [6], moreover, ED is more severe [27] and less responsive to oral drugs in diabetes [28,29], leading to reduced quality of life [13,2].

Advanced age and longer duration of diabetes have been associated with an increased risk of ED in diabetic patients [8,14,30]. Whether hyperglycemia is a risk factor for the development of ED in diabetic men is still not clear. Diabetes is commonly associated with hypertension, hyperlipidemia, overweight and obesity, metabolic syndrome, smoking, sedentary lifestyles, and autonomic neuropathy, which are recognized as risk factors for ED [18].

The use of several medications frequently assumed by diabetic patients, such use of β-blockers, thiazide diuretics, spironolactone, antidepressants, and certain fibrates, have all been associated with an additive deleterious effect on diabetic ED [31,32].

**Pathogenesis of ED in Diabetes**

Erection is a neurovascular event that involves spinal and supra spinal pathways. The final common pathway involves the release of Nitric Oxide (NO) from both endothelial cells and neurons. The causes of erectile dysfunction in men with diabetes are complex and involve impairments in nerve, blood vessel, and muscle function. The pathogenesis of ED in diabetes is multifactorial, as it depends on both psychological and organic factors (which play major roles in ED) [18], as well as psychological and relationship issues, which often coexist. The proposed mechanisms of ED in diabetic patients are represented by vasculopathy, neuropathy, visceral adiposity, insulin resistance, and hypogonadism.

Diabetic vasculopathy concerns macroangiopathy, microangiopathy, and endothelial dysfunction. Macrovascular disease in diabetes corresponds to the atherosclerotic damage in the blood vessels, which limits blood flow to the penis. As mentioned, several cardiovascular risk factors associated with diabetes contribute to the genesis of penile arterial insufficiency [19,20,23] all of them converge on endothelial dysfunction, which represents the common denominator leading to vascular ED. For this reason regarding sexual activity, erectile dysfunction may be a significant sign in the case of suspected diabetes and the early diagnosis of vasculopathy in patients with diabetes. The chronic insult of hyperglycemia on the endothelium results in endothelial dysfunction, which has been suggested as the link between ED and CVD [33]. Endothelial dysfunction in diabetics is manifested as the decreased bioavailability of Nitric Oxide (NO), resulting in insufficient relaxation of the vascular smooth muscle of the corpora cavernosa. The potential mechanisms involved an imbalance between the vasocostrictive and vasorelaxant intracellular pathways favoring increased vasoconstriction [26,34].

Microvascular disease determines ischemic damage in the distal circulation and autonomic and peripheral neuropathy. Both somatic and autonomic neuropathies may contribute to diabetes-induced ED due to the impairment of sensory impulses from the penis to the reflexogenic erectile center [35] and reduced or absent parasympathetic activity necessary for relaxation of the smooth muscle of the corpus cavernosum [36].

**Diagnostic Evaluation**

The first step in evaluating ED is always a detailed medical and sexual history of patients and partners when available. The pathophysiology of ED may be vasculogenic, neurogenic, anatomical, hormonal, drug-induced and/or psychogenic. Taking a comprehensive medical history may reveal one of the many common disorders associated with ED. Sexual history, physical examination, laboratory testing and somespecialised diagnostic tests (e.g. duplex ultrasound of the penis, nocturnal penile tumescence and rigidity test, intracavernous injection test and psychiatric assessment) can be used to diagnosis.

**Treatment of ED**

As a consequence of its multifactorial etiology, the treatment of ED in diabetic men requires a global approach. The first step is to correct the modifiable risk factors and to promote lifestyle changes, whereas the use of Phosphodiesterase 5 (PDE5) inhibitors represents first-line pharmacologic therapy, second-line therapy is other options (eg. Hormonal therapy/Vacuum therapy/LIST/Intracavernosal therapy) and finally the last step is surgical treatment.

**Glucose Control and Lifestyle Modifications**

Tight glucose control, so as to maintain an HbA1c concentration <7%, is recommended for adults with diabetes to minimize the risk of long-term microvascular complications [37]. Although several studies demonstrate an association between poor glycemic control and the risk of ED, it is not clear whether intensive glycemic control may have beneficial effects on erectile function. Many cross-sectional studies have shown that better glycemic control is associated with improved erectile function [38,39].

Lifestyle changes, such as increased physical activity, a Mediterranean diet, and reduced caloric intake, have been associated with the amelioration of erectile function in the general male population. The suggested mechanisms by which weight loss, healthy diet, and physical exercise can improve erectile function include the amelioration of endothelial dysfunction, insulin-resistance, and low-grade inflammatory state associated with diabetes and metabolic diseases—all of which are risk factors for ED [40].

**Pharmacological Therapy and Other Therapies**

Oral PDE5-Is are now regarded as the first-line treatment for erectile dysfunction [41,42]. These drugs facilitate erection by inhibiting the PDE5 enzyme, which is specifically responsible for the degradation of cyclic Guanosine Monophosphate (cGMP) in the cavernous smooth muscles. This inhibition leads to the prolonged activity of cGMP which, in turn, reduces intracellular calcium concentrations, maintains smooth muscle relaxation, and results in rigid penile erections. Sildenafil, vardenafil, and tadalafil are commercially available worldwide. These drugs differ in their time to onset and in their duration of action, but they show the same efficacy and safety profile. All of them have shown their efficacy in diabetic
patients [43], although it has been reported that diabetic men with ED are less responsive to PDE5 inhibitors when compared with nondiabetic men with ED [44]. Moreover, findings from both experimental and clinical studies reported that chronic or daily use of PDE5 inhibitors for ED may significantly improve endothelial dysfunction [45,46]. Mirodenafil is a new option for the treatment of erectile dysfunction in diabetes mellitus patients with sexual dysfunction. It is at least as effective as other PDE5 inhibitors [47]. In addition to treatment, udenafil and mirodenafil may be another option in daily dosing treatment for ED [47,48]. CHD is not an absolute contraindication for PDE5 inhibitors therapy, but particular caution has to be paid in cases of unstable and severe angina pectoris, recent myocardial infarction, certain arrhythmias, poorly controlled hypertension, and concomitant use of nitrates or nitrate donors: before starting therapy with PDE5 inhibitors, diabetic patients should undergo an overall cardiovascular examination [49].

Testosterone Replacement Therapy (TRT) is recommended in men with ED who show low levels of testosterone [50]. Different formulations are available, such as gels, patches, tablets, implants, and injections. In a prospective, randomized, double-blind, placebo-controlled study, transdermal testosterone replacement therapy was associated with beneficial effects on sexual function in men with type 2 diabetes [51]. In the therapy of ED, particularly in patients with late-onset hypogonadism, TRT should be used in cases that are unresponsive to PDE-5 inhibitors, which promotes significant symptomatic relief [52].

Vacuum Erection Devices (VEDs) provide passive engorgement of the corpora cavernosa, together with a constrictor ring placed at the base of the penis to retain blood within the corpora. Thus, erections with these devices are not normal because they do not use physiological erection pathways. Efficacy, in terms of erections satisfactory for intercourse, is as high as 90%, regardless of the cause of ED and satisfaction rates range between 27% and 94% [53].

Penile extracorporal Low-Intensity Shock Wave Therapy (LIST) to the penis has recently emerged as a novel and promising modality in the treatment of erectile dysfunction. LIST has angiogenic properties and stimulates neovascularization. If applied to the corpora cavernosa, LIST can improve penile blood flow and endothelial function. LIST has been shown to have a substantial effect on penile hemodynamics and erectile function in patients with vasculogenic ED. LIST is effective in patients who are responsive to Phosphodiesterase 5 Inhibitors (PDE5i) and can also convert PDE5i nonresponders to responders [54].

Intracavernosal injection of papaverine, phentolamine, and Prostaglandin E1 (PGE1) (alone or in combination), as well as the intracavernosal administration of PGE1, are good alternatives for patients who do not respond to PDE5 inhibitors. Both of these two treatment modalities have demonstrated efficacy in ameliorating erectile function in diabetic patients [55,56].

Surgical Therapy

Penile prosthesis implantation, the third-line treatment for erectile dysfunction, is one of the few successful surgical treatments for erectile dysfunction. Implantation of a penile prosthesis is usually the last resort for treatment of erectile dysfunction, when other modalities have failed or are not preferred by the patient. There are two main types of penile prostheses. The semi-rigid prosthesis is usually easy to implant and lasts longer than the inflatable one. The hydraulic three-piece implant is the most popular penile prosthesis in the USA.

Other surgical treatments for erectile dysfunction include arterial bypass procedures, which are specifically indicated for traumatic injuries of penile arteries (and can potentially lead to cure of the erectile dysfunction), and venous ligation surgery for young men with congenital abnormal venous leakage; however, vascular surgery is rarely done nowadays.

Acknowledgments

The authors thank for your technical help and writing assistance.

Disclosure

The authors report no conflicts of interest in this work.

References

Citation: Ediz C, Altintas R (2014) Diabetes Mellitus and Sexual Dysfunction; A Systematic Review of the Literature with Current Treatment Approaches. J Diabetes Metab Disord 1: 001.


